Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MPO | P05164 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.53 |
| ▸ | KRAS | P01116 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | DPP3 | Q9NY33 | 2/20 | 0.49 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21641795 | 1.00 | DPP4 (0.73) | DPP4CYP2C19KDM4EMEN1LMNA | |
| SCHEMBL6438364 | 1.00 | DPP4 (0.73) | DPP4CYP2C19KDM4EMEN1LMNA | |
| SCHEMBL6438370 | 1.00 | DPP4 (0.73) | DPP4CYP2C19KDM4EMEN1LMNA | |
| SCHEMBL29706750 | 0.96 | DPP4 (0.68) | DPP4CYP2C19KDM4EMEN1LMNA | |
| SCHEMBL12343754 | 0.91 | DPP4 (0.71) | DPP4CYP2C19KDM4EMEN1LMNA | |
| SCHEMBL12343828 | 0.91 | DPP4 (0.71) | DPP4CYP2C19KDM4EMEN1LMNA | |
| SCHEMBL8236885 | 0.90 | DPP4 (0.70) | DPP4CYP2C19KDM4EMEN1LMNA | |
| SCHEMBL12340711 | 0.90 | DPP4 (0.70) | DPP4CYP2C19KDM4EMEN1LMNA | |
| SCHEMBL30051339 | 0.89 | DPP4 (0.58) | DPP4CYP2C19KDM4EMEN1LMNA | |
| SCHEMBL16667737 | 0.88 | DPP4 (0.68) | DPP4CYP2C19KDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315296-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ CHEILJEDANG CORPORATION (KR) | 2024-09-26 | — | — | US | claimed |
| CN-118344369-A | Method for preparing eptifibatide impurity I based on diphenylphosphonooxy label in auxiliary mode | 山西医科大学 | 2024-07-16 | — | — | CN | claimed |
| EP-4364582-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ Cheiljedang Corporation (KR) | 2024-05-08 | — | — | EP | claimed |
| CN-117205297-A | Application of small molecular peptide WP in preparation of functional product for relieving Alzheimer's disease | 中国海洋大学 | 2023-12-12 | — | — | CN | claimed |
| WO-2023277549-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | 씨제이제일제당 (주) | 2023-01-05 | — | — | WO | claimed |
| CN-109438555-B | Preparation method of non-natural antioxidant peptide | 浙江海洋大学 | 2022-07-29 | — | — | CN | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4504166-B1 | TOPICAL FORMULATION FOR USE IN THE TREATMENT OR PREVENTION OF ITCHY DRY SKIN | MC2 THERAPEUTICS LTD (GB) | 2026-04-29 | — | — | EP | disclosed |
| EP-3604503-B1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO KK (JP) | 2026-03-18 | — | — | EP | disclosed |
| EP-4684030-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2026-01-28 | — | — | EP | disclosed |
| EP-4642898-A1 | GENETICALLY MODIFIED CELLS COMPRISING A NUCLEIC ACID ENCODING A CD40L BINDING AGENT AND USES THEREOF | AffyXell Therapeutics Co., Ltd. (KR) | 2025-11-05 | — | — | EP | disclosed |
| CN-109438555-B | Preparation method of non-natural antioxidant peptide | 浙江海洋大学 | 2022-07-29 | — | — | CN | disclosed |
| CN-109438555-B | Preparation method of non-natural antioxidant peptide | 浙江海洋大学 | 2022-07-29 | — | — | CN | disclosed |
| WO-2022094237-A1 | ENZYME ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022094262-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
| EP-3947743-A1 | METHODS OF DIAGNOSING DISEASE | 4D Pharma Cork Limited (IE) | 2022-02-09 | — | — | EP | disclosed |
| US-20200040308-A1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO CO., INC. (JP) | 2020-02-06 | — | — | US | disclosed |
| EP-3604503-A1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | Ajinomoto Co., Inc. (JP) | 2020-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | DPP4 43/4885CYP2C19 212/4885KDM4E 1136/4885 |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | PIGS, TAS2R13, CEL | DPP4 609/4885CYP2C19 1352/4885KDM4E 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.